GMED · PEAD ↑ 71

Globus Medical reported Q2 2026 EPS of $1.34 on 2026-08-06, beating the $1.12 consensus by $0.22 (+19.6%).

Print-day reaction was a muted +0.67% versus the prior close, with the stock barely moving on the earnings day itself despite the sizable beat. The overnight gap to the T+1 open was the real tell: GMED leapt +8.68%, a sharp after-hours and pre-market re-rating as the market absorbed the magnitude of the EPS outperformance. Over the subsequent two trading days, the stock drifted an additional +3.40%, confirming the initial gap rather than fading it. Cumulative abnormal return of +5.62% versus SPY.US firmly places this in PEAD long territory; the documented drift pattern holds through 2026-11-03.